Parliamentary questions can be asked by any MSP to the Scottish Government or the Scottish Parliamentary Corporate Body. The questions provide a means for MSPs to get factual and statistical information.
Urgent Questions aren't included in the Question and Answers search. There is a SPICe fact sheet listing Urgent and emergency questions.
Displaying 34189 questions Show Answers
To ask the Scottish Government whether it will provide an update on talks with the Scottish Green Party on a potential co-operation agreement.
To ask the Scottish Government what its response is to calls for national parks to allocate 10% of their areas for rewilding.
To ask the Scottish Government what steps it is taking to establish a baseline for marine plastic pollution monitoring.
To ask the Scottish Government whether it will provide an update on the COVID-19 legislation in place.
To ask the Scottish Government what support it offers to people with gambling addiction.
To ask the Scottish Government what impact the COVID-19 pandemic has had on how it prioritises the allocation of support from its (a) International Development and (b) Humanitarian Emergency Fund, and what these priorities are.
To ask the Scottish Government, further to the answer to question S6W-00307 by Ivan McKee on 7 June, whether it will provide an update on whether dancing is permitted at weddings in level 0 protection areas.
To ask the Scottish Government what its response is to calls from the Children and Young People's Commissioner Scotland for a review of nursery guidance, and whether it will publish guidance on safe ways that adults can observe transition events for nursery and primary school pupils.
To ask the Scottish Government when it plans to update the guidance for seating at weddings to take account of the indoor hospitality numbers at COVID-19 protection levels 1 and 0.
To ask the Scottish Government what public interest conditions relating to (a) open licensing, (b) equitable access and, (c) affordability were attached to the public funding of Valneva for the (i) research and development of its inactivated whole virus COVID-19 vaccine and (ii) expansion of manufacturing capacity at its factory in Livingston.